Deficient Expression of PTPN2 Contributes to JAK/STAT3 Hyperactivation in Juvenile Dermatomyositis via Impaired Negative Regulation
This study demonstrates that deficient expression of PTPN2 in juvenile dermatomyositis impairs negative regulation of the JAK/STAT3 signaling pathway, leading to its hyperactivation in both the cytoplasm and mitochondria and subsequent dysregulation of the calcium-regulatory protein SLN.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the human body, muscles are not just engines for movement; they are complex tissues that constantly communicate with the immune system. When this communication goes wrong, it can lead to autoimmune diseases like juvenile dermatomyositis, a rare condition where a child's own immune system mistakenly attacks their muscles and skin. This attack causes painful weakness and distinctive rashes. Scientists have long known that in these patients, a specific signaling pathway acts like a stuck switch, constantly telling the immune system to stay in "attack mode." This pathway, driven by a molecule called interleukin-6, activates a protein known as STAT3. When STAT3 is active, it travels into the cell's command center to turn on genes that fuel inflammation. Normally, the body has built-in brakes to stop this signal once the job is done, but in juvenile dermatomyositis, these brakes seem to be failing, leaving the inflammation unchecked.
A team of researchers at the Children's Hospital of Zhejiang University set out to find out exactly which brake had failed in this disease. They focused on a specific protein called PTPN2, which acts as a negative regulator, meaning its job is to turn off or dampen the activity of STAT3. To investigate, the scientists collected small samples of muscle tissue from children with juvenile dermatomyositis who had not yet started treatment, as well as from healthy children. They grew these muscle cells in the lab to create a living model of the disease. By comparing the genetic activity of the sick cells against the healthy ones, they looked for differences in the genes responsible for turning off the inflammatory signal.
The researchers found a clear and consistent problem in the muscle cells of the children with the disease. While some of the known "brakes" were working normally, the gene responsible for making the PTPN2 protein was significantly quieter in the sick cells than in the healthy ones. In fact, the levels of this protein were substantially reduced in the muscle tissue of the patients, appearing deficient compared to healthy controls. To prove that this lack of PTPN2 was actually causing the problem, the scientists used a precise genetic tool to modify the cells. They took muscle cells from the patients and added extra copies of the PTPN2 gene, effectively giving the cells a working brake. They also created a separate group of healthy cells where they removed the PTPN2 gene to see what would happen.
The results showed a direct cause-and-effect relationship. When the scientists restored the missing PTPN2 in the patient's cells, the overactive STAT3 signal slowed down. The phosphorylation of STAT3, which is the chemical mark that indicates the protein is active and ready to cause damage, dropped significantly. This happened not only in the main part of the cell but also inside the mitochondria, the tiny power plants that generate energy for the muscle. Conversely, when they removed PTPN2 from healthy cells, the STAT3 signal became hyperactive, mimicking the disease state. This confirmed that the deficiency of PTPN2 was a primary driver of the runaway inflammation seen in juvenile dermatomyositis.
The study also uncovered a secondary effect of this broken signaling. The researchers found that when PTPN2 is missing, another protein called sarcolipin increases dramatically. Sarcolipin is a small molecule that regulates how muscles handle calcium, a mineral essential for muscle contraction and relaxation. In the patient's cells, the lack of the PTPN2 brake led to high levels of sarcolipin, which the scientists believe contributes to the muscle weakness and stress characteristic of the disease. When they added PTPN2 back into the patient's cells, the levels of sarcolipin were partially reduced, suggesting that restoring the initial brake could help restore balance to the muscle's calcium management, though the effect was not absolute.
This work provides a clearer picture of why the immune system remains in a constant state of alarm in these children. It is not just that the signal to attack is too strong; it is that the specific mechanism designed to turn that signal off has broken down. By identifying PTPN2 as a key missing piece, the researchers have highlighted a potential target for future therapies. If doctors can find a way to boost the levels of this protein or mimic its function, they might be able to calm the overactive immune response more precisely than current treatments allow. The study suggests that the path to better management of juvenile dermatomyositis may lie in helping the body's own cells regain control of their internal signaling switches.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.